Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Liver Neoplasms 2Carcinoma, Hepatocellular 2Pituitary Neoplasms 1Pancreatic Fistula 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Nelson Syndrome 1Lymphoma, Follicular 1Hypoglycemia 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Liver Neoplasms × pasireotide × Gastrointestinal × Clear all
NCT01469572 2018-10-18

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Emory University

Phase 1 Completed
13 enrolled
EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

NCT01488487 2016-04-07

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
24 enrolled 17 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡